DJIA 18,128.85 31.95 0.18%
NASDAQ 4,981.19 14.05 0.28%
S&P 500 2,100.08 1.55 0.07%
market minute promo

Sarepta Therapeutics (NASDAQ: SRPT)



company name or ticker

BioMarin Takes Aim at Sarepta

BioMarin's acquisition of Prosensa puts it in direct competition with Sarepta.

Big News for Ebola Stocks

Sarepta Therapeutics (SRPT): Heavy Pre-Market Activity

Benzinga's Top #PreMarket Gainers

BioMarin Acquires Prosensa in Deal Valued Up to $840 Million

Celldex Therapeutics To Enter Talks With FDA

Sarepta Initiates Dosing for Study Evaluating Eteplirsen - Analyst Blog

Ebola Stock Short Interest Surprise

Sarepta Therapeutics' (SRPT) CEO Chris Garabedian on 23rd Annual Credit Suisse Healthcare Conference

Sarepta Therapeutics' (SRPT) CEO Chris Garabedian on 23rd Annual Credit Suisse Healthcare Conference Call Transcript

Sarepta Q3 Loss Narrower-Than-Expected, Eteplirsen in Focus - Analyst Blog

See More Articles...